OGT's first dedicated fusion MRD NGS panel targets the roughly one-quarter of AML cases where RNA fusion transcripts, not DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results